MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.biomaterials.2024.122567

Медицинская библиотека · Biomaterials · 2024

Intranasal delivery of low-dose anti-CD124 antibody enhances treatment of chronic rhinosinusitis with nasal polyps.

Wu Jiamin, Jones Natalie, Chao Po-Han, Chan Vanessa, Hohenwarter Lukas, Wu Angeline, Bergamo Marta, Rodríguez-Rodríguez Cristina, Saatchi Katayoun, Liang Alex, Häfeli Urs O, Tan Zheng, Hedtrich Sarah, Andrew Lucas J, Li Shyh-Dar

СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

Frequent injections of anti-CD124 monoclonal antibody (αCD124) over long periods of time are used to treat chronic rhinosinusitis with nasal polyps (CRSwNP). Needle-free, intranasal administration (i.n.) of αCD124 is expected to provide advantages of localized delivery, improved efficacy, and enhanced medication adherence. However, delivery barriers such as the mucus and epithelium in the nasal tissue impede penetration of αCD124. Herein, two novel protamine nanoconstructs: allyl glycidyl ether conjugated protamine (Nano-P) and polyamidoamine-linked protamine (Dendri-P) were synthesized and showed enhanced αCD124 penetration through multiple epithelial layers compared to protamine in mice. αCD124 was mixed with Nano-P or Dendri-P and then intranasally delivered for the treatment of severe CRSwNP in mice. Micro-CT and pathological changes in nasal turbinates showed that these two nano-formulations achieved ∼50 % and ∼40 % reductions in nasal polypoid lesions and eosinophil count, respectively. Both nano-formulations provided enhanced efficacy in suppressing nasal and systemic Immunoglobulin E (IgE) and nasal type 2 inflammatory biomarkers, such as interleukin 13 (IL-13) and IL-25. These effects were superior to those in the protamine formulation group and subcutaneous (s.c.) αCD124 given at a 12.5-fold higher dose. Intranasal delivery of protamine, Nano-P, or Dendri-P did not induce any measurable toxicities in mice.

Для цитирования: Wu Jiamin, Jones Natalie, Chao Po-Han, Chan Vanessa, Hohenwarter Lukas, Wu Angeline, Bergamo Marta, Rodríguez-Rodríguez Cristina, Saatchi Katayoun, Liang Alex, Häfeli Urs O, Tan Zheng, Hedtrich Sarah, Andrew Lucas J, Li Shyh-Dar. Intranasal delivery of low-dose anti-CD124 antibody enhances treatment of chronic rhinosinusitis with nasal polyps.. Biomaterials. 2024. DOI: 10.1016/j.biomaterials.2024.122567.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.